CPP Bone Infection Registry (CPP Infection)
Establish an international registry of over 400 patients with deep infections involving the bone and/or joint from≥20 centers representing all regions of the world with varied hospital and surgeon practice settings to ensure that registry analyses and research reflect typical clinical practice thereby providing optimal guidance for patients, clinicians, and healthcare researchers. Using a data collection platform that minimizes entry burden, collects most information at the time of surgery, and uses Internet technology to minimize data entry. The registry will include:
- baseline patient attributes;
- surgical approach, implants and technology;
- hospital course;
- surgeon and institutional characteristics;
- longitudinal patient outcome,
- post-procedure complications and revisions,
- serum/tissue/drainage samples.
|Bone Infection Staphylococcus Aureus|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Clinical Priority Program: Bone Infection; Use of a Registry on Infection to Improve Patient Outcomes and Research Efforts|
- Details on occurence and treatment of bone infection [ Time Frame: 1 December 2012 ]
- Surgical approach, implants and technology [ Time Frame: 01 December 2012 ]
- Patient outcome [ Time Frame: 01 December 2012 ]
- Post-procedure complications and revisions [ Time Frame: 01 December 2012 ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2018|
|Estimated Primary Completion Date:||June 2018 (Final data collection date for primary outcome measure)|
Establish an international registry with AOCID of over 400 patients with deep infections involving the bone and/or joint from ≥ 20 centers representing all regions of the world with varied hospital and surgeon practice settings to ensure that registry analyses and research reflect typical clinical practice thereby providing optimal guidance for patients, clinicians, and healthcare researchers. Creation of an AOCID Registry for musculoskeletal infection cases will permit better analysis of the causes, contributing factors including patient immune responses, treatments and clinical outcomes of musculoskeletal infections.
- Establish a practice network that includes ≥ 20 geographically distributed centers. These busy practices will be treating patients with varied geographic status to assure balanced representation of diverse patients and practices.
- Establish a Data Coordinating Core team with AOCID using a data collection platform that minimizes entry burden, collects most information at the time of surgery, and uses Internet technology to minimize data entry.
The registry will include:
- baseline patient attributes
- surgical approach, implants and technology
- hospital course
- surgeon and institutional characteristics
- longitudinal patient outcome
- post-procedure complications and revisions
- Establish a Statistical Support team with AOCID to implement cutting-edge statistical techniques including the use of hierarchical generalized linear latent and mixed effects models to address the complex structure and longitudinal nature of registry data. Multivariable predictive models for outcome(s) of infection will be developed.
- Establish an Outcomes Measurement Team with AOCID and Investigators from the CPP team to advance the science of infection-specific and global patient-reported outcomes to support efficient data collection of web-based, longitudinal data in this registry and future comparative effectiveness research.
- Develop new assessment tools and conduct research useful to clinical practice. Establish consensus on the definition of treatment failure- characterized as lack of clinically meaningful improvement in infection, pain or physical function following treatment, validate, and refine prediction algorithms for patients at risk for failure.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01677000
|Contact: Nicole Neutz||+41 44 200 24 firstname.lastname@example.org|
|Contact: Stephen L Kates, MDemail@example.com|
Show 21 Study Locations
|Principal Investigator:||Stephen L Kates, MD||University of Richmond|